Der von Ihnen verwendete Browser wird nicht unterstützt.
Einige Funktionen dieser Website funktionieren möglicherweise nicht ordnungsgemäß. Für eine optimale Benutzererfahrung öffnen Sie diese Website bitte in Chrome, Firefox, Safari oder Edge.

Veröffentlichungen

Kongresse und Publikationen / Veröffentlichungen

Neueste Veröffentlichungen

Bannerbild mit blauem und rotem Molekül Ob Sie auf diese Artikel Zugriff haben, hängt möglicherweise von Ihren Zeitschriftenabonnements oder die Ihrer Institution ab.

BGB-A333

Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours — 2023

BGB-DXP593

SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial — 2023

Lifirafenib

Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase Inhibitor, in patients with solid tumors — 2020
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors — 2020

Ociperlimab

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors — 2023

Pamiparib

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial — 2023
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study — 2022
Human mass balance and metabolite profiling of [14-C]-pamiparib, a poly (ADP-Ribose) polymerase inhibitor, in patients with advanced cancer — 2021
Pamiparib monotherapy for patients with germline BRCA1/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study — 2021
Phase 1a/1b dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours — 2021
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors; an open-label, parallel-group phase 1 study — 2021
Discovery of pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development — 2020
Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer — 2020
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor — 2020
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1A/B trial — 2019

Sitravatinib

SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma — 2024

Tislelizumab

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors — 2024
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma — 2024
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302 — 2024
Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small cell lung cancer (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial — 2024
Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours — 2023
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors — 2023
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors — 2023
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial — 2023
Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer — 2023
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer — 2023
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer — 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309) — 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study — 2023
Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a Phase 3 randomized clinical trial — 2023
Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia — 2023
Examining the impact of tislelizumab added to chemotherapy on health-related quality-of-life outcomes in previously untreated patients with nonsquamous non–small cell lung cancer — 2022
HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma — 2022
Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors — 2022
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma — 2022
Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (rationale-208): a multicenter, non-randomized, open-label, phase 2 trial — 2022
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study — 2022
Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life — 2022
Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial — 2022
Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma — 2021
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma — 2021
The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: results from a phase 3 randomized clinical trial — 2021
Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis — 2021
Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer (RATIONALE 304): a randomized phase 3 trial — 2021
Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial — 2021
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage — 2021
A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients — 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors — 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma — 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study — 2020
Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma — 2020
A human peripheral blood mononuclear cell (PBMC) engrafted humanized xenograft model for translational immuno-oncology (I-O) research — 2019
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1A/B trial — 2019
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma — 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study — 2019
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions — 2018

Zanubrutinib

Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia — 2024
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib — 2024
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database — 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies — 2024
A phase 1, open-label, fixed-sequence, drug-drug interaction study of zanubrutinib with rifabutin in healthy volunteers — 2023
Health-related quality of life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab — 2023
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial — 2023
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma — 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: an updated pooled analysis — 2023
Molecular associations of response to the new generation BTK inhibitor zanubrutinib in marginal zone lymphoma — 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment — 2023
ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma — 2023
View publication in plain language
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study — 2023
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis — 2023
Zanubrutinib in patients with relapsed/refractory hairy cell leukemia — 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: an expanded-access study of 50 patients in the United States — 2023
Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study — 2023
Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia — 2023
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies — 2022
A phase II study of zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma — 2022
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies — 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study — 2022
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study — 2022
Zanubrutinib monotherapy for naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: a pooled analysis of three studies — 2022
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma — 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma — 2022
Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia — 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial — 2022
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial — 2022
A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory Waldenström macroglobulinemia — 2021
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib — 2021
Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator — 2021
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor — 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies — 2021
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma — 2021
The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase Inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma — 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma — 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study — 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma — 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials — 2021
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment — 2020
A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma — 2020
A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study — 2020
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma — 2020
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-GP, and BCRP — 2020
No QTc prolongation with zanubrutinib: results of concentration-QTc analysis from a thorough QT study in healthy subjects — 2020
Nonclinical safety assessment of zanubrutinib: a novel irreversible BTK inhibitor — 2020
Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B-cell malignancies — 2020
Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase — 2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study — 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma — 2020
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial — 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up — 2020
Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion — 2020
Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase — 2019
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton’s tyrosine kinase inhibitor) in Asian and non‑Asian healthy subjects — 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL — 2019
A head-to-head phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia — 2018
Zurück zu Kongresse und Publikationen

Manche Inhalte sind nur auf Englisch verfügbar.

Powered by Translations.com GlobalLink OneLink Software